淀粉样蛋白PET严重程度与认知障碍的终生及10年绝对风险
该回顾性纵向队列研究基于Mayo Clinic老化研究人群,纳入认知正常且年龄≥50岁的参与者,计算不同淀粉样蛋白PET centiloid值下的终生和10年认知障碍绝对风险。结果显示,MCI和痴呆的终生风险随centiloid值升高而单调增加,且APOE ε4携带者风险更高。
要点
- 淀粉样蛋白PET centiloid值越高,认知正常者终生MCI和痴呆风险越高。
- 相同centiloid组内,APOE ε4携带者终生及10年绝对风险高于非携带者。
- 起始年龄对10年绝对风险的影响比centiloid值更显著。
核心结论
- 认知正常个体中,MCI和痴呆的终生及10年绝对风险随阿尔茨海默病生物学严重程度增加而升高。
研究设计与样本
- 回顾性纵向队列研究,基于美国Olmsted County的Mayo Clinic老化研究数据。
- 纳入5158名认知正常且入组时年龄≥50岁的参与者,以及700名MCI患者进行分析。
- 主要预测因子为基于淀粉样蛋白PET centiloid值的阿尔茨海默病生物学严重程度。
主要发现
- MCI和痴呆的终生风险随centiloid值增加单调上升(p<0·0001),centiloid是效应最大的预测因子。
- 75岁起始的男性APOE ε4携带者终生MCI风险:centiloid 5为56·2%(95% CI 50·5-61·9),centiloid 100为76·5%(70·5-82·4)。
- 75岁起始的女性APOE ε4携带者终生MCI风险:centiloid 5为68·9%(63·7-74·1),centiloid 100为83·8%(78·5-89·1)。
- 各centiloid组内,APOE ε4携带者的终生和10年MCI及痴呆绝对风险均高于非携带者(p<0·0001)。
- centiloid值可预测10年MCI和痴呆绝对风险(p<0·0001),但起始年龄的影响更显著(p<0·0001)。
临床怎么用
- 对于认知正常但淀粉样蛋白PET异常的患者,可参考centiloid值、APOE ε4状态和起始年龄评估未来认知障碍的绝对风险。
- 高centiloid值提示较高的终生认知障碍风险,有助于未来治疗干预的风险-获益评估。
局限性
- 研究为回顾性设计,可能受选择偏倚影响。
- 研究外结局需通过建模估计,可能引入不确定性。
- 既往退出研究者的痴呆发生率是留在研究者中的两倍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A key knowledge gap concerns the lifetime risk of developing cognitive impairment among individuals who are cognitively unimpaired with abnormal Alzheimer's disease biomarkers. Our aim was to compute lifetime and 10-year absolute risk of cognitive impairment as a function of continuous amyloid PET. METHODS: In this retrospective, longitudinal cohort study of data from participants of the population-based Mayo Clinic Study of Aging (Olmsted County, MN, USA), we computed lifetime and 10-year absolute risk of cognitive impairment in participants who were cognitively unimpaired and aged 50 years or older at enrolment. The primary predictor of interest was biological Alzheimer's disease severity, based on amyloid PET centiloid value. Starting age, sex, and APOE ε4 carriership status were also predictors. Outcomes were incident mild cognitive impairment (MCI), dementia, and death, which were ascertained or estimated via multistate hidden Markov modelling both in study and out of study. FINDINGS: Between Nov 29, 2004, and Dec 2, 2024, 5158 participants (2623 [51%] women and 2535 [49%] men) who are cognitively unimpaired and 700 (307 [44%] women and 393 [56%] men) with MCI were included for analysis. Lifetime risk of MCI and dementia increased monotonically with increasing centiloid value (p<0·0001), which was the predictor with the largest effect. Lifetime risk of MCI for male APOE ε4 carriers who are cognitively unimpaired at a starting age of 75 years was 56·2% (95% CI 50·5-61·9) for centiloid 5, 60·2% (54·9-65·6) for centiloid 25, 71·0% (65·2-76·7) for centiloid 50, 75·2% (69·1-81·2) for centiloid 75, and 76·5% (70·5-82·4) for centiloid 100. Lifetime risk of MCI for female APOE ε4 carriers who are cognitively unimpaired at a starting age of 75 years was 68·9% (63·7-74·1) for centiloid 5, 71·3% (66·6-76·0) for centiloid 25, 77·6% (72·5-82·7) for centiloid 50, 81·2% (76·7-85·7) for centiloid 75, and 83·8% (78·5-89·1) for centiloid 100. Within each centiloid group, and for both men and women, lifetime and 10-year absolute risk for MCI and dementia was greater for APOE ε4 carriers than for non-carriers (p<0·0001). Biological severity of Alzheimer's disease was a predictor of 10-year absolute risk of MCI and dementia (p<0·0001); however, starting age (p<0·0001) had a more prominent effect. The rate of incident dementia was two times greater among individuals who had previously left the study than those who remained in the study. INTERPRETATION: Lifetime and 10-year absolute risk for MCI and dementia among individuals who are currently cognitively unimpaired increase with increasing biological severity of Alzheimer's disease. This information should be important for risk-benefit evaluation of therapeutic interventions in the future. The high lifetime risk in participants with higher centiloid values addresses academic controversies concerning risk of future impairment associated with biomarkers of Alzheimer's disease among individuals who are cognitively unimpaired. Ascertainment and modelling of out-of-study outcomes are necessary for accurate lifetime risk estimates. FUNDING: US National Institutes of Health, GHR Foundation, and the Alexander Family.
引用
- Jack CR, Hu M, Wiste HJ, et al. Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study. Lancet Neurol. 2025. PMID: 41240917. doi:10.1016/S1474-4422(25)00350-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。